Carbylan Therapeutics Inc Stock
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Carbylan Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Carbylan Therapeutics Inc in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
B****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Carbylan Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Carbylan Therapeutics Inc | - | - | - | - | - | - | - |
| Pharma Mar S.A. | 0.190% | 0.633% | -0.687% | -1.303% | 5.714% | 129.780% | 10.517% |
| Clinuvel Pharmaceuticals | 3.770% | -5.025% | -10.376% | -17.961% | -20.283% | -46.641% | -66.416% |
| Optibiotix Health plc | 0.000% | -2.290% | -11.111% | -48.387% | -14.667% | -85.185% | -88.870% |
News
KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000
Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals (NASDAQ:KALV), reported the exercise of 33,800 options into common stock and the immediate sale of those shares for a total
DRI Healthcare Trust Q1 Earnings Call Highlights
DRI Healthcare Trust (TSE:DHT.UN) reported higher first-quarter income and expanded margins as management said the royalty investment company continued to benefit from its post-internalization cost
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
KalVista Pharmaceuticals (NASDAQ:KALV), a developer of oral therapies for rare diseases, closed Wednesday at $26.67, up 38.62%. The stock moved higher after news that Italy’s Chiesi Group will